<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706173</url>
  </required_header>
  <id_info>
    <org_study_id>071982</org_study_id>
    <nct_id>NCT00706173</nct_id>
  </id_info>
  <brief_title>Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>A Randomized Double-blind Placebo-controlled Cross-over Trial of Hydrocortisone for Post-traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Developing novel and effective pharmacologic interventions for this post-traumatic stress
      disorder is important. The investigators propose to replicate findings of an earlier
      published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do
      so in a more meaningful way, the investigators will conduct a larger but similar randomized
      double-blind placebo-controlled, cross-over design treatment study examining the use of low
      dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.

      The investigators hypothesize that, as described by Aerni et al. (2004), administration of
      daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for
      re-experiencing types (e.g., flashbacks, nightmares)of symptoms. The investigators also hope
      to examine potential predictors and moderators of treatment response based on subjects'
      clinical characteristics, as well as serum cortisol and ACTH levels.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit eligible subjects for the trial.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>Week 0,2,4,6,8,10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions - Improvement (CGI-I)</measure>
    <time_frame>Week 0,2,4,6,8,10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Inventory (SDI)</measure>
    <time_frame>Week 0,4,6,10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory - 18 item (BSI-18)</measure>
    <time_frame>Week 0,2,4,6,8,10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone 10-20 mg PO daily for 4 weeks.</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <other_name>cortisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo &quot;10-20 mg&quot; PO daily for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male military veterans

          -  Between the ages of 18-65 years old

          -  Generally good medical health with no clinically significant abnormalities on physical
             examination, electrocardiogram, or laboratory findings

          -  Ability to provide informed consent and comply with requirements of study protocol

          -  No specific contraindications to hydrocortisone

          -  Clinically predominant DSM-IV diagnosis of PTSD

          -  Score of ≥ 40 on Clinician Administered PTSD Scale [CAPS]

        Exclusion Criteria:

          -  History of moderate to severe traumatic brain injury, seizure or organic mental
             illness

          -  Lifetime history of schizophrenia, bipolar disorder, other psychotic disorder, or
             depression with a score of ≥ 16 on the 17-item Hamilton Depression Rating Scale
             (Hamilton, 1960), active suicidal ideation

          -  Unstable medical illness

          -  Subjects undergoing any formal psychotherapy within 3 months of enrollment

          -  Subjects that meet criteria for substance dependence during the last 6 months

          -  History of adverse reaction to corticosteroids.

          -  Concurrent use of other psychotropic medication (e.g. benzodiazepines, antipsychotics)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray B Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.veryshy.org</url>
    <description>UCSD Anxiety Disorders Research Program</description>
  </link>
  <reference>
    <citation>Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, Nitsch RM, Schnyder U, de Quervain DJ. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry. 2004 Aug;161(8):1488-90.</citation>
    <PMID>15285979</PMID>
  </reference>
  <reference>
    <citation>Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhäusler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry. 2001 Dec 15;50(12):978-85.</citation>
    <PMID>11750894</PMID>
  </reference>
  <reference>
    <citation>Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A, Rothenhäusler HB, Krauseneck T, Nollert G, Kapfhammer HP. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry. 2004 Mar 15;55(6):627-33.</citation>
    <PMID>15013832</PMID>
  </reference>
  <reference>
    <citation>Olff M, Güzelcan Y, de Vries GJ, Assies J, Gersons BP. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology. 2006 Nov;31(10):1220-30. Epub 2006 Nov 1.</citation>
    <PMID>17081699</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Murray B. Stein</name_title>
    <organization>University of California, San Diego</organization>
  </responsible_party>
  <keyword>Post-traumatic stress disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>Cortisol</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>pharmacological treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

